A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer - Concepedia

Concepedia

Publication | Open Access

A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer

DOI Full Paper Access

252

Citations

33

References

2013

Year

Amanda Eustace, Navin Mani, Paul N. Span, Joely J. Irlam, Janet Taylor, Guy Betts, Helen Denley, Crispin Miller, Jarrod J. Homer, Ana M. Rojas,

Clinical Cancer Research

Abstract

The 26-gene hypoxia signature predicts benefit from hypoxia-modifying treatment in laryngeal cancer. These findings will be evaluated in a prospective clinical trial.

References

	Year	Citations

Page 1